Home Health News Pfizer Analyst Says COVID-19-Driven Rally Not Backed By Vaccine Economics – Yahoo Finance

Pfizer Analyst Says COVID-19-Driven Rally Not Backed By Vaccine Economics – Yahoo Finance

9 min read
0
0
101

[ad_1]

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR announced an agreement with the U.S. government Wednesday to supply an initial consignment of 100 million doses of the&nbsp;coronavirus vaccine the companies are developing in the event of future emergency use authorization or full approval for the shot.&nbsp;” data-reactid=”19″>Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR announced an agreement with the U.S. government Wednesday to supply an initial consignment of 100 million doses of the coronavirus vaccine the companies are developing in the event of future emergency use authorization or full approval for the shot. 

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="US Government Deal Positive For Pfizer: Pfizer’s deal is positive for the nation as well as the company, BofA Securities analyst Geoff Meacham said in a note.&nbsp;” data-reactid=”20″>US Government Deal Positive For Pfizer: Pfizer’s deal is positive for the nation as well as the company, BofA Securities analyst Geoff Meacham said in a note. 

The U.S. government has the optionality to acquire an additional 500 million doses the analyst said. Assuming a two-dose regimen, 600 million doses could cover over 90% of the U.S. population, he said. 

For Pfizer, the vaccine news is a positive development, Meacham said.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="That said, the analyst does not see the vaccine programs as being fully derisked is looking ahead to additional data as Phase 3 trials get underway.” data-reactid=”27″>That said, the analyst does not see the vaccine programs as being fully derisked is looking ahead to additional data as Phase 3 trials get underway.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Pfizer’s Vaccine Economics: At the $20 price point implied by the U.S. government’s contract value and assuming a 50-50 gross profit split between Pfizer and BioNTech, Meacham expects the vaccine to be helpful to Pfizer’s P&amp;L.” data-reactid=”28″>Pfizer’s Vaccine Economics: At the $20 price point implied by the U.S. government’s contract value and assuming a 50-50 gross profit split between Pfizer and BioNTech, Meacham expects the vaccine to be helpful to Pfizer’s P&L.

This is especially true as company contends with portfolio risks that include the adjuvant Ibrance failure, recent pipeline programs that failed to stand apart from competition and the Eliquis patent ruling, the analyst said. 

Pfizer shares have added about $30 billion in value since their recent low in June, mainly on COVID-19 news. The valuation implies about 1.5 billion doses sold at the $20 price point, Meacham said. 

To justify the valuation, Pfizer may have to sell about 6 billion doses at a 50% margin, according to BofA — more than the sell-side firm’s assumed number of patients treated worldwide through 2030 .

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="PFE Rating, Price Action: Meacham maintained a Neutral rating on Pfizer with a $38 price target.&nbsp;” data-reactid=”32″>PFE Rating, Price Action: Meacham maintained a Neutral rating on Pfizer with a $38 price target. 

At last check, Pfizer shares were down 0.18% at $38.49. 

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Related Links:” data-reactid=”34″>Related Links:

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Intel, Texas Instruments To Kickstart Chip Earnings With ‘Better-Than-Feared’ Results ” data-reactid=”35″>Intel, Texas Instruments To Kickstart Chip Earnings With ‘Better-Than-Feared’ Results

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Nvidia Analysts See Multibillion-Dollar Opportunity In Automated Driving Deal With Mercedes-Benz ” data-reactid=”36″>Nvidia Analysts See Multibillion-Dollar Opportunity In Automated Driving Deal With Mercedes-Benz

Latest Ratings for PFE

Date Firm Action From To
Jun 2020 SVB Leerink Initiates Coverage On Market Perform
Jun 2020 JP Morgan Maintains Neutral
Apr 2020 Barclays Maintains Equal-Weight

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="View More Analyst Ratings for PFE
View the Latest Analyst Ratings” data-reactid=”40″>View More Analyst Ratings for PFE
View the Latest Analyst Ratings

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="See more from Benzinga” data-reactid=”41″>See more from Benzinga

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.” data-reactid=”45″>© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Let’s block ads! (Why?)

[ad_2]
Source link

Load More Related Articles
Load More By admin
Load More In Health News

Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also

UK coronavirus variant cases doubling every 10 days in US, study finds – Fox News

[ad_1] The highly-contagious COVID-19 variant first detected in the United Kingdom is now …